pharmaceuticals pillar  idera pharmaceuticals inc  zoominfocom pillar pharmaceuticals v lp  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors pillar pharmaceuticals v lp check out list of companies and businesses related to pillar pharmaceuticals v lp find out pillar pharmaceuticals v lp address and contact details view other people related to pillar pharmaceuticals v lp  coworkers colleagues companions etc address pillar invest offshore sal starco ctr bloc b rd floor omar daouk street beirut  lebanon companies related to pillar pharmaceuticals v lp cikcompany namepositioncompany addressidera pharmaceuticals inc sidney street cambridge  pillar pharmaceuticals v lp on the web persons related to pillar pharmaceuticals v lp  idera pharmaceuticals incnamepositioncity capital gp llcnew york capital gp llc owner new york lpnew york lpnew yorkumari abdulwahabbeirutumari abdulwahabbeirutsudhir agrawalpresident of research cambridgesudhir agrawalceo  cso cambridgesudhir agrawalpresident of research cambridgesudhir agrawalcambridgetauntonrigby alisondirector lincolnrobert g andersencfo  vp oper and planning cambridgerobert g andersencfo  vp oper and planning cambridgerobert d arbeitvp clinical development cambridgerobert d arbeitvp clinical development cambridgelouis j arcudi iiichief financial officer cambridgelouis j arcudichief financial officer cambridgebaker biotech capital gp llcnew yorkbaker biotech capital gp llc owner new yorkbaker biotech capital ii gp llcnew yorkbaker biotech capital ii z gp llcnew yorkbaker biotech capital ii z gp llcnew yorkbaker biotech capital iii gp llcnew yorkbaker biotech capital iii gp llcnew yorkbaker biotech capital iii z gp llcnew yorkbaker biotech capital iii z gp llcnew yorkbaker bros advisors gp llcnew yorkbaker bros advisors llcdirector new yorkbaker bros advisors lpnew yorkbaker bros capital gp llcnew yorkbaker bros capital gp llc owner new yorkbaker brothers life sciences capital gp llc owner new yorkbaker brothers life sciences capital gp llcnew yorkbaker brothers life sciences capital gp llc owner new yorkbaker brothers life sciences lpnew yorkfelix bakerfelix bakernew yorkfelix bakernew yorkfelix bakernew yorkjulian bakerdirector julian bakernew yorkjulian bakerdirector new yorkjulian bakernew yorkalice bexoncambridgealice bexonvp clinical development cambridgelouis md brennerchief medical officer cambridgemark j caseysenior vp  general counsel marlboroughrobert c fletchersr vp bus dev  strategy extonrobert c fletchersr vp bus dev  strategy cambridgejames a geraghtydirector framinghamjames a geraghtydirector cambridgemark alan goldbergdirector needhammark alan goldbergdirector cambridgemaxine gowendirector w conshohockenc keith hartleydirector greenwichjoanna horobinchief medical officer cambridgerobert w karrdirector essexrobert w karrdirector st louismalcolm maccossdirector seabrook islandrussell martinsenior vp of drug development cambridgevincent milanopresident  ceo vincent milanopresident and ceo cambridgehans muellerdirector west chesterkelvin neuberkeleypillar invest corpdirector beirutpillar invest corpdirector cambridgepillar pharmaceuticals i lpbeirutpillar pharmaceuticals i lpbeirutpillar pharmaceuticals i lpdirector beirutpillar pharmaceuticals i lpbeirutpillar pharmaceuticals i lpbeirutpillar pharmaceuticals ii lpbeirutpillar pharmaceuticals ii lpbeirutpillar pharmaceuticals ii lpbeirutpillar pharmaceuticals iii lpbeirutpillar pharmaceuticals iv lpbeirutwilliam s reardondirector hinghamalison taunton rigbydirector lincolnsenator investment group lpnew yorksenator investment group lp owner new yorkeve elizabeth slaterdirector cambridgeeve elizabeth slaterdirector short hillstimothy m sullivanvp development programs cambridgetimothy m sullivanvp development programs cambridgejohn peter wolf iiigeneral counsel cambridgejames b wyngaardendirector durhamjames b wyngaardendirector durhamjonathan michael yinglingsvp of early development cambridgepaul c zamecnikdirector bostonyoussef el zeindirector cambridgeyoussef el zeindirector cambridgeyoussef el zeindirector cambridgeyoussef el zeinbeirutyoussef el zeinbeirutyoussef el zeinbeirutyoussef el zeinbeirut stock screener  yahoo financehomemailflickrtumblrnewssportsfinancecelebrityanswersgroupsmobilemoreyahoosearchsearchus markets open in  hrs  minssp futures dow futures insider transactionsdefault criteriainsider  restricted shareholder transactions of  resultsresults were generated a few mins ago pricing data is updated frequently currency in usdsymboldatesharesproceedstransaction detailsidrananastatement of ownershipsean hannity responds to claim he ran up a  tab at trumps hotel after flying in a yearold lobster from mainebusiness insidersolar eclipse  stay in the tualatin valleythe tualatin valleysponsoredtrump’s unwitting legacy could be universal health coverageyahoo financeyahoo small businessdata disclaimerhelpsuggestionsprivacyabout our adsterms updated pillar pharmaceuticals i lp  ceo founder businessman  profile directorpedianet  list of ceos founders board members and company directors pillar pharmaceuticals i lp check out list of companies and businesses related to pillar pharmaceuticals i lp find out pillar pharmaceuticals i lp address and contact details view other people related to pillar pharmaceuticals i lp  coworkers colleagues companions etc address pillar invest offshore sal starko ctr bloc b rd flr omar daouk st beirut  lebanon companies related to pillar pharmaceuticals i lp cikcompany namepositioncompany addressidera pharmaceuticals incdirector  sidney street cambridge  pillar pharmaceuticals i lp on the web persons related to pillar pharmaceuticals i lp  idera pharmaceuticals incnamepositioncity capital gp llcnew york capital gp llc owner new york lpnew york lpnew yorkumari abdulwahabbeirutumari abdulwahabbeirutsudhir agrawalpresident of research cambridgesudhir agrawalceo  cso cambridgesudhir agrawalpresident of research cambridgesudhir agrawalcambridgetauntonrigby alisondirector lincolnrobert g andersencfo  vp oper and planning cambridgerobert g andersencfo  vp oper and planning cambridgerobert d arbeitvp clinical development cambridgerobert d arbeitvp clinical development cambridgelouis j arcudi iiichief financial officer cambridgelouis j arcudichief financial officer cambridgebaker biotech capital gp llcnew yorkbaker biotech capital gp llc owner new yorkbaker biotech capital ii gp llcnew yorkbaker biotech capital ii z gp llcnew yorkbaker biotech capital ii z gp llcnew yorkbaker biotech capital iii gp llcnew yorkbaker biotech capital iii gp llcnew yorkbaker biotech capital iii z gp llcnew yorkbaker biotech capital iii z gp llcnew yorkbaker bros advisors gp llcnew yorkbaker bros advisors llcdirector new yorkbaker bros advisors lpnew yorkbaker bros capital gp llcnew yorkbaker bros capital gp llc owner new yorkbaker brothers life sciences capital gp llc owner new yorkbaker brothers life sciences capital gp llcnew yorkbaker brothers life sciences capital gp llc owner new yorkbaker brothers life sciences lpnew yorkfelix bakerfelix bakernew yorkfelix bakernew yorkfelix bakernew yorkjulian bakerdirector julian bakernew yorkjulian bakerdirector new yorkjulian bakernew yorkalice bexoncambridgealice bexonvp clinical development cambridgelouis md brennerchief medical officer cambridgemark j caseysenior vp  general counsel marlboroughrobert c fletchersr vp bus dev  strategy extonrobert c fletchersr vp bus dev  strategy cambridgejames a geraghtydirector framinghamjames a geraghtydirector cambridgemark alan goldbergdirector needhammark alan goldbergdirector cambridgemaxine gowendirector w conshohockenc keith hartleydirector greenwichjoanna horobinchief medical officer cambridgerobert w karrdirector essexrobert w karrdirector st louismalcolm maccossdirector seabrook islandrussell martinsenior vp of drug development cambridgevincent milanopresident  ceo vincent milanopresident and ceo cambridgehans muellerdirector west chesterkelvin neuberkeleypillar invest corpdirector beirutpillar invest corpdirector cambridgepillar pharmaceuticals ii lpbeirutpillar pharmaceuticals ii lpbeirutpillar pharmaceuticals ii lpbeirutpillar pharmaceuticals iii lpbeirutpillar pharmaceuticals iv lpbeirutpillar pharmaceuticals v lpbeirutwilliam s reardondirector hinghamalison taunton rigbydirector lincolnsenator investment group lpnew yorksenator investment group lp owner new yorkeve elizabeth slaterdirector cambridgeeve elizabeth slaterdirector short hillstimothy m sullivanvp development programs cambridgetimothy m sullivanvp development programs cambridgejohn peter wolf iiigeneral counsel cambridgejames b wyngaardendirector durhamjames b wyngaardendirector durhamjonathan michael yinglingsvp of early development cambridgepaul c zamecnikdirector bostonyoussef el zeindirector cambridgeyoussef el zeindirector cambridgeyoussef el zeindirector cambridgeyoussef el zeinbeirutyoussef el zeinbeirutyoussef el zeinbeirutyoussef el zeinbeirut potentially same personnamecitycountrypillar pharmaceuticals i lpbeirutlebanonpillar pharmaceuticals i lpbeirutlebanonpillar pharmaceuticals i lpbeirutlebanonpillar pharmaceuticals i lpbeirutlebanon microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft idera pharmaceuticals inc idra  insider monkey companies  see all hedge funds  see all insiders  see all institutional investors  see all click here to see all results for sorry no results has been found matching your query adblocker detected dear valued visitor we have noticed that you are using an ad blocker software although advertisements on the web pages may degrade your experience our business certainly depends on them and we can only keep providing you highquality research based articles as long as we can display ads on our pages to view this article you can disable your ad blocker and refresh this page or simply login we only allow registered users to use ad blockers you can sign up for free by clicking here or you can login if you are already a member home  insider trading  idera pharmaceuticals inc  profile idera pharmaceuticals inc idra get email alerts profile hedge fund holdings insider purchases insider sales institutional investors holdings news get email alerts profile hedge fund holdings insider purchases insider sales other institutional investors holdings news sector biological products no disgnostic substances related insiders el youssef zein large shareholder director  s william reardon director  baker bros advisors gp llc director  el youssef zein large shareholder director  s william reardon director  baker bros advisors gp llc director   lp director   lp director  baker brothers life sciences lp director  baker bros advisors lp director  felix baker director  julian baker director  a james geraghty director  alan mark goldberg director  maxine gowen director  pillar pharmaceuticals ii lp large shareholder director  pillar invest corp large shareholder director  pillar pharmaceuticals i lp large shareholder director  michael jonathan yingling svp of early development  c robert fletcher sr vp bus dev  strategy  j louis iii arcudi chief financial officer  j mark casey senior vp  general counsel  joanna horobin chief medical officer  vincent milano president  ceo  sudhir agrawal president of research  pillar pharmaceuticals v lp large shareholder director  pillar pharmaceuticals iv lp large shareholder director  pillar pharmaceuticals iii lp large shareholder director  elizabeth eve slater director  iii peter john wolf general counsel  md louis brenner chief medical officer  malcolm maccoss director  w robert karr director  m timothy sullivan vp development programs  umari abdulwahab director  kelvin neu director  d robert arbeit vp clinical development  keith c hartley director  senator investment group lp large shareholder  b james wyngaarden director  hans mueller director  show all insiders  hedge fund holdings login to see all holdings  sign up filing period                            last updated on june    pm based on sec f filings last update june    pm no hedge fund shares value x activity  port  broadfin capitalkevin kotler      baker bros advisorsjulian baker and felix baker      palo alto investorswilliam leland edwards     nine chapters capital managementchao ku     alyeska investment groupanand parekh     login to see all holdings  sign up its free insider trading purchases see all insider price amount relationship remaning holdings date form  baker   director   filing baker   director   filing zein   large shareholder director   filing gowen   director   filing geraghty   director   filing insider trading sales see all insider price amount relationship remaining holdings date form  pillar   large shareholder director   filing pillar   large shareholder director   filing pillar   large shareholder director   filing pillar   large shareholder director   filing pillar   large shareholder director   filing institutional investors holdings login to see all holdings  sign up filing period                             no name shares value x  port  lau associates llc    login to see all holdings  sign up its free news see all is idera pharmaceuticals inc idra a good stock to buy investing in hedge funds can bring large profits but it’s not for everybody since hedge funds are available only for highnetworth individuals they generate significant returns for investors to read more december th   hedge funds news  comments why traders are keenly watching twitter zumiez idera and more in this article well find out why twitter inc nysetwtr zumiez inc nasdaqzumz idera pharmaceuticals inc nasdaqidra yahoo inc nasdaqyhoo and verizon communications inc nysevz are read more october th   market movers news  comments idera pharmaceuticals inc idra are hedge funds right about this stock hedge funds and other investment firms run by legendary investors like israel englander and ray dalio are entrusted to manage billions of dollars of accredited investors money because they are without read more december th   hedge funds news  comments why are these stocks surging today at a time when all three indices are in the red in anticipation of a federal reserve interest rate hike later in the month shares of keurig green mountain inc nasdaqgmcr sodastream international read more december th   news  comments kevin kotler’s broadfin capital joins healthcor in idera broadfin capital idera pharmaceuticals just now kevin kotlers broadfin capital disclosed adding idera pharmaceuticals inc nasdaqidra to its equity portfolio in a filing with the securities and read more october th   hedge funds news  comments healthcor management reports a new  stake in idera pharmaceuticals healthcor management idera pharmaceuticals in a g with the sec released this morning arthur cohen and joseph healeys healthcor management reported a new  stake in idera pharmaceuticals inc read more october th   hedge funds news  comments idera pharmaceuticals inc idra  biotech could be the best chance to triple your money in this market yet due to fundamental underlying support such as the improvement in european economies the fed being unlikely to change its accommodative monetary policy and overall solid corporate earnings i retain read more august th   news  comments click here to see all news hedge fund resource center how to beat the market by  percentage points why track hedge funds download a free edition why you should dump your hedge funds  things you didnt know about hedge funds billionaire hedge funds warren buffett berkshire hathaway  david einhorn greenlight capital  george soros soros fund management  t boone pickens bp capital  jim simons renaissance technologies  leon cooperman omega advisors  carl icahn icahn capital lp  steve cohen point asset management  john paulson paulson  co  david tepper appaloosa management lp  home hedge funds markets blog authors about us contact us privacy policy terms of use site map all text and design is copyright  koala guide llc all rights reserved pillar pharmaceuticals i lp sc da filing concerning idra on  whalewisdom search all search f filers only search sec filer search stocks only search mgmt inv cos only etfs only search active schedule da filed by pillar pharmaceuticals i lp total shares  subject company idera pharmaceutical  view complete ownership history backtest filed as of date  event date  overall  ownership  reporting persons name solevoting power sharedvoting power soledispositive power shareddispositive power aggregateamount owned percentof class pillar pharmaceuticals i lp       pillar pharmaceuticals ii lp       pillar pharmaceuticals iii lp       pillar pharmaceuticals iv lp       pillar pharmaceuticals v lp       pillar invest corporation       youssef el zein       view original filing on edgars raw filing contents txt   hdrsgml    accession number  conformed submission type sc da public document count  filed as of date  date as of change  group members pillar invest corp group members pillar pharmaceuticals ii lp group members pillar pharmaceuticals iii lp group members pillar pharmaceuticals iv lp group members pillar pharmaceuticals v lp group members youssef el zein subject company company data company conformed name idera pharmaceuticals inc central index key  standard industrial classification biological products no diagnostic substances  irs number  state of incorporation de fiscal year end  filing values form type sc da sec act  act sec file number  film number  business address street   sidney street city cambridge state ma zip  business phone  mail address street   sidney street city cambridge state ma zip  former company former conformed name hybridon inc date of name change  filed by company data company conformed name pillar pharmaceuticals i lp central index key  irs number  state of incorporation e fiscal year end  filing values form type sc da business address street  co pillar invest offshore sal street  starco center bloc b fl omar daouk st city beirut state m zip  business phone  mail address street  co pillar invest offshore sal street  starco center bloc b fl omar daouk st city beirut state m zip  sc da  ddscdahtm sc da sc da     securities and exchange commission washington dc      schedule d rule d information to be included in statements filed pursuant to rule dla and amendments thereto filed pursuant to rule da amendment no      idera pharmaceuticals inc name of issuer common stock  par value per share title of class of securities k cusip number youssef el zein co pillar invest offshore sal starco center bloc b third floor omar daouk street beirut  lebanon name address and telephone number of person authorized to receive notices and communications october   date of event which requires filing of this statement     if the filing person has previously filed a statement on schedule g to report the acquisition that is the subject of this schedule d and is filing this schedule because of rule de df or dg check the following box  ☐      the remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page the information required on the remainder of this cover page shall not be deemed to be filed for the purpose of section  of the securities exchange act of  the act or otherwise subject to the liabilities of that section of the act but shall be subject to all other provisions of the act         continued on the following pages page  of  pages cusip no k    d    page  of  pages         names of reporting persons   pillar pharmaceuticals i lp      check the appropriate box if a member of a group   a  ☐        b  ☒      sec use only        source of funds   wc      check box if disclosure of legal proceedings is required pursuant to item d or e   ☐      citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power             shared voting power             sole dispositive power           shared dispositive power       aggregate amount beneficially owned by each reporting person       check box if the aggregate amount in row  excludes certain shares   ☐    percent of class represented by amount in row        type of reporting person   pn    this amendment no  to schedule d is filed by pillar pharmaceuticals i lp pillar pillar pharmaceuticals ii lp pillar ii pillar pharmaceuticals iii lp pillar iii pillar pharmaceuticals iv lp pillar iv pillar pharmaceuticals v lp pillar v pillar invest corporation pillar gp and youssef el zein together with pillar pillar ii pillar iii pillar iv pillar v and pillar gp the reporting persons the reporting persons expressly disclaim status as a group for purposes of this amendment no  to schedule d pillar pillar ii pillar iii pillar iv pillar v and pillar gp expressly disclaim beneficial ownership of any shares of the issuers common stock par value  per share the common stock held directly by mr el zein and mr el zein expressly disclaims beneficial ownership of any shares of common stock held directly by pillar pillar ii pillar iii pillar iv pillar v and indirectly by pillar gp including the besancon shares pillar pillar ii pillar iii pillar iv and pillar v expressly disclaim beneficial ownership of any shares of common stock over which pillar gp has investment discretion the besancon shares pursuant to that certain advisory agreement the advisory agreement between pillar gp and participations besancon besancon besancon is an investment fund having no affiliation with the reporting persons pillar directly holds i  shares of common stock and ii warrants the series d pillar warrants representing  shares of common stock which are presently exercisable subject to the conversion cap pillar ii directly holds i  shares of common stock and ii warrants the series e pillar ii warrants representing  shares of common stock which are presently exercisable subject to the conversion cap pursuant to the advisory agreement pillar gp also has investment discretion over  of common stock series e pillar warrants representing  shares of common stock which are presently exercisable subject to the conversion cap  of common stock and warrants representing  shares of common stock each acquired in a public offering of the issuer on may   the may  offering which are presently exercisable and in each case are held directly by besancon and  shares of common stock of the issuer acquired in a public offering of the issuer on september   the september  offering and  shares of common stock of the issuer acquired in a public offering of the issuer on october   the october  offering which are held directly by besancon pillar iii directly holds  shares of common stock of the issuer pillar iv directly holds  shares of common stock of the issuer acquired in the september  offering mr el zein directly holds  shares of common stock and options to buy  shares of common stock which are exercisable within sixty days of the closing date pillar v directly holds  shares of common stock of the issuer acquired in the october  offering pursuant to rule d of the securities exchange act of  the exchange act the number of shares of common stock beneficially owned by the reporting persons and the applicable percentage represent prior to the application of the conversion cap and the voting cap a shares of common stock issued upon pillars exercise of its series d pillar warrants assuming that no other holder of series d pillar warrants exercisable for shares of common stock exercised any such series d pillar warrants b shares of common stock issued upon pillar iis exercise of its series e pillar warrants assuming that no other holder of series e pillar warrants exercisable for shares of common stock exercised any such series e pillar warrants c shares of common stock issued upon besancons exercise of its series e pillar warrants assuming that no other holder of series e pillar warrants exercisable for shares of common stock exercised any such series e pillar warrants d shares of common stock issued upon pillar iiis exercise of its pillar iii offering warrants assuming that no other holder of pillar iii offering warrants exercisable for shares of common stock exercised any such pillar iii offering warrants and e shares of common stock issued upon mr el zeins exercise of his vested options assuming that no other holder of options exercisable for shares of common stock exercises any such options in addition the terms of the series d pillar warrants and the series e pillar warrants together the warrants provide that the issuer shall not effect any exercise of warrants for a number of shares of common stock in excess of that number of shares of common stock which upon giving effect to such exercise would cause a the aggregate number of shares of common stock beneficially owned by pillar and pillar ii and their affiliates to exceed  of the total number of issued and outstanding shares of common stock of the issuer as of the closing date or b the combined voting power of the securities of the issuer beneficially owned by pillar and pillar ii and their affiliates to exceed  of the combined voting power of all of the securities of the issuer outstanding as of the closing date collectively the conversion cap in addition the terms of the preferred stock provide that for so long as the total number of shares of common stock beneficially owned by pillar and pillar ii and their affiliates exceeds  subject to an increase to  upon approval of the stockholders of the issuer as described below of the then outstanding shares of common stock in any election of directors and in any other vote to be taken by the stockholders of the issuer pillar and pillar ii and their affiliates will vote such number of shares of common stock beneficially owned by them in excess of  subject to an increase to  upon approval of the stockholders of the issuer as described below in the same manner as and in the same proportion to the votes cast by the other holders of the issuers common stock or other voting securities the voting cap accordingly the  shares of common stock reported above represent  of the  shares of common stock outstanding as of the consummation of the october  offering the closing date cusip no k    d    page  of  pages         names of reporting persons   pillar pharmaceuticals ii lp      check the appropriate box if a member of a group   a  ☐        b  ☒      sec use only        source of funds   wc      check box if disclosure of legal proceedings is required pursuant to item d or e   ☐      citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power             shared voting power             sole dispositive power           shared dispositive power       aggregate amount beneficially owned by each reporting person       check box if the aggregate amount in row  excludes certain shares   ☐    percent of class represented by amount in row        type of reporting person   pn cusip no k    d    page  of  pages         names of reporting persons   pillar pharmaceuticals iii lp      check the appropriate box if a member of a group   a  ☐        b  ☒      sec use only        source of funds   wc      check box if disclosure of legal proceedings is required pursuant to item d or e   ☐      citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power             shared voting power             sole dispositive power           shared dispositive power       aggregate amount beneficially owned by each reporting person       check box if the aggregate amount in row  excludes certain shares   ☐    percent of class represented by amount in row        type of reporting person   pn cusip no k    d    page  of  pages         names of reporting persons   pillar pharmaceuticals iv lp      check the appropriate box if a member of a group   a  ☐        b  ☒      sec use only        source of funds   wc      check box if disclosure of legal proceedings is required pursuant to item d or e   ☐      citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power             shared voting power             sole dispositive power           shared dispositive power       aggregate amount beneficially owned by each reporting person       check box if the aggregate amount in row  excludes certain shares   ☐    percent of class represented by amount in row        type of reporting person   pn cusip no k    d    page  of  pages         names of reporting persons   pillar pharmaceuticals v lp      check the appropriate box if a member of a group   a  ☐        b  ☒      sec use only        source of funds   wc      check box if disclosure of legal proceedings is required pursuant to item d or e   ☐      citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power             shared voting power             sole dispositive power           shared dispositive power       aggregate amount beneficially owned by each reporting person       check box if the aggregate amount in row  excludes certain shares   ☐    percent of class represented by amount in row        type of reporting person   pn cusip no k    d    page  of  pages         names of reporting persons   pillar invest corporation      check the appropriate box if a member of a group   a  ☐        b  ☒      sec use only        source of funds   af      check box if disclosure of legal proceedings is required pursuant to item d or e   ☐      citizenship or place of organization   cayman islands number of shares beneficially owned by each reporting person with             sole voting power             shared voting power             sole dispositive power           shared dispositive power       aggregate amount beneficially owned by each reporting person       check box if the aggregate amount in row  excludes certain shares   ☐    percent of class represented by amount in row        type of reporting person   pn cusip no k    d    page  of  pages         names of reporting persons   youssef el zein      check the appropriate box if a member of a group   a  ☐        b  ☒      sec use only        source of funds   af      check box if disclosure of legal proceedings is required pursuant to item d or e   ☐      citizenship or place of organization   france and lebanon number of shares beneficially owned by each reporting person with             sole voting power             shared voting power             sole dispositive power           shared dispositive power       aggregate amount beneficially owned by each reporting person       check box if the aggregate amount in row  excludes certain shares   ☐    percent of class represented by amount in row        type of reporting person   in cusip no k    d    page  of  pages   item  security and issuer this amendment no  to schedule d relates to the common stock par value  per share the common stock of idera pharmaceuticals inc a corporation organized under the laws of the state of delaware the company or the issuer with its principal executive offices located at  sidney street cambridge ma  information given in response to each item shall be deemed incorporated by reference in all other items as applicable   item  identity and background a this amendment no  to schedule d is being filed by pillar pharmaceuticals i lp a cayman island limited partnership pillar pillar pharmaceuticals ii lp a cayman island limited partnership pillar ii pillar pharmaceuticals iii lp a cayman island limited partnership pillar iii pillar pharmaceuticals iv lp a cayman island limited partnership pillar iv pillar pharmaceuticals v lp a cayman island limited partnership pillar v pillar invest corporation a cayman island exempted company pillar gp and youssef el zein each of the foregoing persons or entities is referred to herein as a reporting person or collectively as the reporting persons pillar is the direct holder of certain warrants the series d pillar warrants to purchase shares of common stock described in this amendment no  to schedule d pillar ii is the direct holder of certain warrants the series e pillar ii warrants to purchase shares of common stock more fully described in this amendment no  to schedule d pillar iii is the direct holder of certain shares of common stock the pillar iii common stock and certain warrants the pillar iii offering warrants to purchase shares of common stock more fully described in this amendment no  to schedule d pillar iv is the direct holder of certain shares of common stock the pillar iv common stock and pillar v is the direct holder of certain shares of common stock the pillar v common stock mr el zein is the direct holder of certain shares of common stock and options to purchase shares of common stock described in this amendment no  to schedule d pillar pillar ii pillar iii pillar iv and pillar v are a private investment funds engaged in the business of acquiring holding and disposing of investments in various companies pillar gp is the general partner of pillar pillar ii pillar iii pillar iv and pillar v pursuant to that certain advisory agreement the advisory agreement between pillar gp and participations besancon besancon pillar gp also has investment discretion over certain shares of series e preferred stock and series e pillar warrants held directly by besancon and certain shares of common stock of the issuer and warrants representing shares of common stock each acquired in a public offering of the issuer on may   the may  offering which are presently exercisable and in each case are held directly by besancon and certain shares of common stock of the issuer acquired in a public offering of the issuer on september   the september  offering and in a public offering of the issuer on october   the october  offering held directly by besancon  besancon is an investment fund having no affiliation with the reporting persons mr el zein is a director and controlling stockholder of pillar gp b the business address of each of the foregoing reporting persons is co pillar invest offshore sal starco center bloc b third floor omar daouk street beirut  lebanon c youssef el zein is a director and controlling stockholder of pillar gp pillar gps principal business consists of investment management d during the last five years none of the reporting persons has been convicted in a criminal proceeding excluding traffic violations or similar misdemeanors e during the last five years none of the reporting persons were a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment decree or final order enjoining future violations of or prohibiting or mandating activities subject to federal or state securities laws or finding any violation with respect to such laws f youssef el zein is a citizen of france and the republic of lebanon   item  source and amount of funds or other consideration the information set forth in item  hereof is hereby incorporated by reference into this item  as applicable   item  purpose of transaction series d financing convertible preferred stock and warrant purchase agreement on november   pillar and the issuer entered into a convertible preferred stock and warrant purchase agreement the series d purchase agreement pursuant to which pillar agreed to acquire from the issuer i  shares of series d preferred stock and ii series d warrants to purchase  shares of common stock for an aggregate purchase price of  the transaction closed on november   the series d closing date the source of funds for the purchase was the working capital of pillar cusip no k    d    page  of  pages   limitations on conversion and exercise the terms of the series d preferred stock and the series d warrants provide that the issuer shall not effect i any conversion of series d preferred stock or ii any exercise of series d warrants for a number of shares of common stock in excess of that number of shares of common stock which upon giving effect to such conversion or exercise as the case may be would cause a the aggregate number of shares of common stock beneficially owned by pillar and its affiliates to exceed  of the total number of issued and outstanding shares of common stock of the issuer as of the series d closing date or b the combined voting power of the securities of the issuer beneficially owned by pillar and its affiliates to exceed  of the combined voting power of all of the securities of the issuer outstanding as of the series d closing date as described below the limitation on the exercise of the series d warrants was amended pursuant to the warrant amendment as of the date of this filing the series d preferred stock has been converted to common stock of the issuer standstill the series d purchase agreement provides that for so long as the total number of shares of common stock beneficially owned by pillar and its affiliates exceeds  of the then outstanding shares of common stock neither pillar nor its affiliates will directly or indirectly unless specifically invited in writing by the issuer to do so a effect or seek initiate offer or propose whether publicly or otherwise or participate in any acquisition of any securities or beneficial ownership thereof or assets of the issuer any tender or exchange offer merger consolidation or other business combination involving the issuer any recapitalization restructuring liquidation dissolution or other extraordinary transaction with respect to the issuer or any solicitation of proxies or consents to vote any voting securities of the issuer provided that this clause a shall not restrict the ability of any director of the issuer that is affiliated with pillar to i acquire exercise or dispose of any stock options or other equity securities of the issuer received as compensation for serving as a director or ii perform his or her duties as a director of the issuer   b form join or in any way participate in a group with respect to any securities of the issuer c otherwise act alone or in concert with others to seek to control or influence the management the companys board of directors the board or policies of the issuer d take any action which could reasonably be expected to force the issuer to make a public announcement regarding any of the types of matters set forth in clause a b or c above or   e enter into any agreements discussions or arrangements with any third party with respect to any of the foregoing this standstill provision shall not restrict pillars ability to exercise its preemptive rights as more fully described below under the heading preemptive rights voting on any matter presented to the stockholders of the issuer for their action or consideration at any meeting of stockholders of the corporation each holder of outstanding shares of series d preferred stock shall be entitled to cast a number of votes equal to the number of whole shares of common stock into which the shares of series d preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter the series d purchase agreement provides that for so long as the total number of shares of common stock beneficially owned by pillar and its affiliates exceeds  of the then outstanding shares of common stock in any election of directors and in any other vote to be taken by the stockholders of the issuer whether taken at an annual or special meeting of stockholders or by written action pillar and its affiliates will vote such number of shares of common stock beneficially owned by pillar and its affiliates in excess of  in the same manner as and in the same proportion to the votes cast by the other holders of the companys common stock or other voting securities as described below this voting limitation was amended pursuant to the purchase agreement amendment preemptive rights the series d purchase agreement provides that in the event the issuer on or prior to the earlier of i november   and ii the day that pillar holds a number of shares of series d preferred stock including shares of common stock issued upon conversion of the series d preferred stock which is less than  of the number of shares of series d preferred stock purchased by pillar proposes to cusip no k    d    page  of  pages   a privately sell and issue securities of the issuer pillar shall have the option to purchase on the same terms and conditions offered by the issuer to the other purchasers of such securities in such additional financing up to that percentage of the securities sold in such additional financing equal to a the number of shares then held by pillar as compared to b the total number of shares then outstanding which pro rata amount shall not exceed  of such additional financing or b enter into a loan financing for the purpose of raising capital and not for the purpose of purchasing equipment or privately sell and issue convertible debt securities or preferred stock of the issuer that ranks senior to the preferred stock pillar shall have the option to participate in such loan financing or other senior financings on the same terms and conditions offered by the issuer to the other participants or purchasers of securities in such senior financings up to that percentage of the amount of the loan financing or of the securities sold in such senior financing equal to the product of i a fraction the numerator of which equals the number of shares then held by pillar and the denominator of which equals the total number of shares issued to pillar and ii if the closing date of the senior financing is on or prior to i november    ii november    or iii november    registration rights agreement in connection with the series d purchase agreement pillar entered into a registration rights agreement dated november   the series d registration rights agreement with the issuer the series d registration rights agreement provides that the company will file a resale registration statement the series d resale registration statement covering the shares of common stock issuable upon conversion of the series d preferred stock and exercise of the series d warrants the issuer agreed to use its reasonable best efforts to cause to become effective the series d resale registration statement on or prior to february   if i the series d resale registration statement is not declared effective on or before march   or ii after the series d resale registration statement has been declared effective sales of any of the registrable securities as defined in the series d registration rights agreement cannot be made pursuant to such series d resale registration statement because such series d resale registration statement has been suspended except as a result of a permitted suspension as provided in the series d registration rights agreement then the issuer shall pay to pillar an amount equal to the product of a the aggregate purchase price of the series d preferred stock then held by pillar multiplied by b one hundredths  for each thirty  day period thereafter notwithstanding the foregoing in no event shall the issuer be obligated to make payments to pillar in an aggregate amount that exceeds  of the aggregate purchase price paid by pillar for the series d preferred stock the issuer will pay all registration expenses other than underwriting discounts and commissions related to the issuers performance of the series d registration rights agreement the series d registration rights agreement contains customary crossindemnification provisions the foregoing descriptions of the series d purchase agreement and the series d registration rights agreement and of the terms the certificate of designations preferences and rights of the series d preferred stock and the form of series d warrant issued to pillar collectively the series d transaction documents do not purport to be complete and are qualified in their entirety by the terms of each such document which are attached hereto as exhibit  exhibit  exhibit  and exhibit  respectively and are incorporated herein by reference cusip no k    d    page  of  pages   series e financing convertible preferred stock and warrant purchase agreement on november   pillar ii participations besancon and the issuer entered into a convertible preferred stock and warrant purchase agreement the series e purchase agreement pursuant to which i pillar ii acquired from the issuer a  shares of series e preferred stock convertible into  shares of common stock and b series e warrants to purchase  shares of common stock and ii participations besancon acquired from the issuer a  shares of series e preferred stock convertible into  shares of common stock and b series e warrants to purchase  shares of common stock for an aggregate purchase price of  the transaction closed on november   the november closing date in connection with the closing of the transaction abdulwahab umari a managing partner of pillar gp was elected to the board upon the recommendation of its nominating and corporate governance committee effective immediately following the closing of the transactions contemplated by the series e purchase agreement the source of funds for the purchase by pillar ii was the working capital of pillar ii and the source of funds for the purchase by besancon was the working capital of besancon as of the date of this filing the series e preferred stock has been converted to common stock of the issuer limitations on transfer the series e purchase agreement provides restrictions on the transfer of any securities issued to pillar ii and besancon including securities convertible into or exercisable for common stock pursuant to the series e purchase agreement including to not sell or transfer any such securities in one or a series of transactions if such transfer would in the aggregate result in the transfer more than  of the then outstanding combined voting power of the outstanding securities of the company excluding from this restriction certain transfers to permitted transferees or in connection with an underwritten public offering by the company that has been approved by the board limitations on conversion and exercise the terms of the series e preferred stock and the series e warrants provide that the issuer shall not effect i any conversion of series e preferred stock or ii any exercise of series e warrants for a number of shares of common stock in excess of that number of shares of common stock which upon giving effect to such conversion or exercise as the case may be would cause a the aggregate number of shares of common stock beneficially owned by pillar ii besancon andor its affiliates to exceed  subject to an increase to  upon the approval by the stockholders of the company of the issuance and sale by the company to pillar ii and besancon together with all prior issuances and sales to pillar of a number of shares of common stock including securities convertible into or exercisable for common stock that is greater than  of the outstanding common stock or outstanding voting power of the company after such issuance and sale in accordance with nasdaq listing rule b the nasdaq proposal of the total number of issued and outstanding shares of common stock of the issuer as of the november closing date or b the combined voting power of the securities of the issuer beneficially owned by pillar ii besancon andor its affiliates to exceed  subject to an increase to  upon stockholder approval of the nasdaq proposal of the combined voting power of all of the securities of the issuer outstanding as of the november closing date standstill the series e purchase agreement provides that for so long as the total number of shares of common stock beneficially owned by pillar ii besancon andor its affiliates exceeds  of the then outstanding shares of common stock neither pillar ii besancon nor their respective affiliates will directly or indirectly unless specifically invited in writing by the issuer to do so a effect or seek initiate offer or propose whether publicly or otherwise or participate in any acquisition of any securities or beneficial ownership thereof or assets of the issuer any tender or exchange offer merger consolidation or other business combination involving the issuer any recapitalization restructuring liquidation dissolution or other extraordinary transaction with respect to the issuer or any solicitation of proxies or consents to vote any voting securities of the issuer provided that this clause a shall not restrict the ability of any director of the issuer that is affiliated with pillar ii or besancon to i acquire exercise or dispose of any stock options or other equity securities of the issuer received as compensation for serving as a director or ii perform his or her duties as a director of the issuer b form join or in any way participate in a group with respect to any securities of the issuer c otherwise act alone or in concert with others to seek to control or influence the management board or policies of the issuer d nominate or otherwise support the election of any person as a director of the company except as approved by the board subject to certain exceptions e take any action which could reasonably be expected to force the issuer to make a public announcement regarding any of the types of matters set forth in clause a b c or d above or cusip no k    d    page  of  pages   f enter into any agreements discussions or arrangements with any third party with respect to any of the foregoing this standstill provision shall not restrict pillar iis or besancons ability to exercise its preemptive rights as more fully described below under the heading preemptive rights voting protective provisions for so long as at least  shares of series e preferred stock subject to adjustment remain outstanding the company has agreed that it will not directly or indirectly a amend the certificate of incorporation or bylaws of the company in a manner that adversely and uniquely affects the series e preferred stock b except as expressly permitted by the certificate of designations for the series e preferred stock purchase or redeem or pay or declare any dividend or make any distribution on any shares of capital stock of the company or c recapitalize or reclassify any of the common stock without in each case the written consent or affirmative vote of the holders of at least  of the then outstanding shares of series e preferred stock in addition to any other vote required by law or the certificate of incorporation unless and until the stockholders of the company approve the nasdaq proposal the series e preferred stock will have no voting rights subject to and effective upon the date that the stockholders of the company approve the nasdaq proposal each holder of outstanding shares of series e preferred stock will be entitled to cast a number of votes equal to the lesser of a the number of whole shares of common stock into which the shares of series e preferred stock held by such holder are convertible and b the product of the voting adjustment percentage as defined in the certificate of designations for the series e preferred stock multiplied by the number of whole shares of common stock into which the shares of series e preferred stock held by such holder are convertible the intent of the voting adjustment percentage is to provide that the maximum aggregate voting power that the holders of series e preferred stock and their affiliates may hold does not exceed  of the total outstanding voting power of the company at any time the voting adjustment percentage does not modify the provisions set forth in the series e purchase agreement that require the pillar ii besancon and their affiliates to vote any shares held by them in excess of the number of shares equal to  or  as applicable of the outstanding common stock including shares of common stock issuable upon conversion or exercise of securities that are convertible into or exercisable for shares of common stock held by them and their affiliates in the same manner and percentage as the holders of the common stock other than pillar ii besancon and their affiliates vote on such matter as more fully described below the series e purchase agreement provides that for so long as the total number of shares of common stock beneficially owned by pillar ii besancon andor its affiliates exceeds  subject to an increase to  upon stockholder approval of nasdaq proposal of the then outstanding shares of common stock in any election of directors and in any other vote to be taken by the stockholders of the issuer whether taken at an annual or special meeting of stockholders or by written action pillar ii besancon andor its affiliates will vote such number of shares of common stock beneficially owned by pillar ii besancon andor its affiliates in excess of  subject to an increase to  upon stockholder approval of nasdaq proposal in the same manner as and in the same proportion to the votes cast by the other holders of the companys common stock or other voting securities each of pillar ii and besancon agreed to refrain from exercising any dissenters rights or rights of appraisal under applicable law at any time with respect to any sale of the company to the extent such sale has been approved by the board preemptive rights the series e purchase agreement provides that in the event the issuer on or prior to the earlier of i november   and ii the day that pillar ii or besancon respectively holds a number of shares of series e preferred stock including shares of common stock issued upon conversion of the series e preferred stock which is less than  of the number of shares of series e preferred stock purchased by pillar ii or besancon respectively proposes to a privately sell and issue securities of the issuer pillar ii and besancon respectively shall have the option to purchase on the same terms and conditions offered by the issuer to the other purchasers of such securities in such additional financing up to that percentage of the securities sold in such additional financing equal to a the number of shares then held by each of pillar ii and besancon respectively as compared to b the total number of shares then outstanding which pro rata amount shall not exceed  subject to an increase to  upon stockholder approval of nasdaq proposal of such additional financing or b enter into a loan financing for the purpose of raising capital and not for the purpose of purchasing equipment or privately sell and issue convertible debt securities or preferred stock of the issuer that ranks senior to the series e preferred stock each of pillar ii and besancon respectively shall have the option to participate in such loan financing or other senior financings on the same terms and conditions offered by the issuer to the other participants or purchasers of securities in such senior financings up to that percentage of the amount of the loan financing or of the securities sold in such senior financing equal to the product of i a fraction the numerator of which equals the number of shares then held by each of pillar ii and besancon respectively and the denominator of which equals the total number of shares issued to each of pillar ii and besancon respectively and cusip no k    d    page  of  pages   ii if the closing date of the senior financing is on or prior to i november    ii november    or iii november    automatic adjustments to series d preferred stock and series d warrants as a result of the transactions contemplated by the series e purchase agreement the conversion price of the series d preferred stock automatically adjusted downward to  and the exercise price of the series d warrants automatically adjusted downward to  registration rights agreement in connection with the series e purchase agreement pillar ii and besancon entered into a registration rights agreement dated november   the series e registration rights agreement with the issuer the series e registration rights agreement provides that the company will file a resale registration statement the series e resale registration statement covering the shares of common stock issuable upon conversion of the series e preferred stock and exercise of the series e warrants the issuer agreed to use its reasonable best efforts to cause to become effective the series e resale registration statement on or prior to february   if i the series e resale registration statement is not declared effective on or before march   or ii after the series e resale registration statement has been declared effective sales of any of the registrable securities as defined in the series e registration rights agreement cannot be made pursuant to such series e resale registration statement because such series e resale registration statement has been suspended except as a result of a permitted suspension as provided in the series e registration rights agreement then the issuer shall pay to pillar ii and besancon an amount equal to the product of a the aggregate purchase price of the series e preferred stock then held by pillar ii and besancon multiplied by b one hundredths  for each thirty  day period thereafter notwithstanding the foregoing in no event shall the issuer be obligated to make payments to pillar ii and besancon in an aggregate amount that exceeds  of the aggregate purchase price paid by pillar ii and besancon for the series e preferred stock the issuer will pay all registration expenses other than underwriting discounts and commissions related to the issuers performance of the series e registration rights agreement the series e registration rights agreement contains customary crossindemnification provisions amendment no  to series d convertible preferred stock and warrant purchase agreement in connection with the series e purchase agreement pillar entered into amendment no  to convertible preferred stock and warrant purchase agreement dated november   the purchase agreement amendment with the issuer the purchase agreement amendment provides that for so long as the total number of shares of common stock beneficially owned by pillar or its affiliates exceeds  subject to an increase to  upon stockholder approval of the nasdaq proposal of the then outstanding shares of common stock in any election of directors and in any other vote to be taken by the stockholders of the issuer whether taken at an annual or special meeting of stockholders or by written action pillar or its affiliates will vote such number of shares of common stock beneficially owned by pillar or its affiliates in excess of  subject to an increase to  upon stockholder approval of the nasdaq proposal in the same manner as and in the same proportion to the votes cast by the other holders of the companys common stock or other voting securities pillar agreed to refrain from exercising any dissenters rights or rights of appraisal under applicable law at any time with respect to any sale of the company to the extent such sale has been approved by the board the purchase agreement amendment also provides for certain restrictions on the transfer of any securities issued to pillar including securities convertible into or exercisable for common stock pursuant to the series d purchase agreement including to not sell or transfer any such securities in one or a series of transactions if such transfer would in the aggregate result in the transfer more than  of the then outstanding combined voting power of the outstanding securities of the company excluding from this restriction certain transfers to permitted transferees or in connection with an underwritten public offering by the company that has been approved by the board amendment no  to common stock purchase warrant in connection with the series e purchase agreement pillar entered into amendment no  to common stock purchase warrant dated november   the warrant amendment with the issuer the warrant amendment provides that the exercise limitation set forth therein shall be amended to increase the  limitation on exercise to  upon the companys receipt of stockholder approval of the nasdaq proposal the foregoing descriptions of the series e purchase agreement and the series e registration rights agreement and of the terms the certificate of designations preferences and rights of the series e preferred stock and the form of series e warrant issued to pillar and besancon the purchase agreement amendment and the warrant amendment collectively the series e transaction documents do not purport to be complete and are qualified in their entirety by the terms of each such document which are attached hereto as exhibit  exhibit  exhibit  exhibit  exhibit  and exhibit  respectively and are incorporated herein by reference cusip no k    d    page  of  pages   amendments to series d and series e april  amendment agreement on april   pillar i and pillar ii entered into an agreement with the issuer pursuant to which in connection with a public offering of the issuer on may   the offering pillar i irrevocably agreed to waive and not exercise the rights powers preferences and other terms of the series d preferred stock under section  of the certificate of designations preferences and rights of series d preferred stock the series d certificate of designations including without limitation the right to require the issuer to purchase all or any portion of the shares of the issuers series d preferred stock at a price equal to the original series d preferred stock purchase price per share plus all accrued or declared but unpaid dividends thereon upon the occurrence of specified fundamental changes such as mergers consolidations business combinations stock purchases or similar transactions resulting in a person or group unaffiliated with any holder of the series d preferred stock owning  or more of the outstanding voting securities of the issuer or successor entity under the agreement the issuer and pillar i and pillar ii agreed among other things        to an amendment to the series d certificate of designations for the series d preferred stock that would cause        the dividend provisions of the series d certificate of designations to change the date after which the issuer may elect to pay dividends in shares of its common stock from december   to october   and to allow for the payment of such dividends in shares of a tobecreated new series of nonvoting preferred stock in the event that payment of such dividends may not be made in shares of its common stock and        in connection with the waiver of the right to require the issuer to purchase the series d preferred stock upon the occurrence of specified fundamental changes to modify the series d certificate of designations to provide in the event of a sale of the issuer for the distribution of any assets that remain available for distribution to the issuers stockholders after payment to the holders of the issuers series a convertible preferred stock and any other class of the issuers capital stock that ranks senior to the series d preferred stock to the holders of the series d preferred stock on a pro rata basis with the holders of the issuers common stock series e preferred stock and such new series of nonvoting preferred stock and        to an amendment to the certificate of designations preferences and rights of series e preferred stock the series e certificate of designations that        modified the dividend provisions of the series e certificate of designations to allow for the payment of dividends in shares of the issuers common stock commencing october   and        allowed for the payment of dividends in shares of a tobecreated new series of nonvoting preferred stock in the event that payment of such dividends may not be made in shares of the issuers common stock as a result of the application of the beneficial ownership and voting power limitations set forth in the series e certificate of designations in addition the issuer agreed to seek approval from its stockholders at the  annual meeting of stockholders of amendments to the series d certificate of designations and series e certificate of designations to effect these changes to the dividend provisions of the series d preferred stock and series e preferred stock the redemption rights of the holders of the series d preferred stock and the rights of the holders of the series d preferred stock to distributions in the event of a sale of the issuer each of pillar i and pillar ii agreed        to vote and to cause its affiliates to vote all shares of the issuers voting stock held by pillar i pillar ii and their affiliates and over which they have the power to vote in favor of such amendments and        not to and to cause their affiliates not to sell or transfer any shares of common stock series d preferred stock or series e preferred stock held by them to any person entity or group unless such proposed transferee agrees in a written instrument executed by such transferee the applicable entity and the issuer to take and hold such securities subject to among other things the agreement and to be bound by the terms of the agreement including the waiver of rights voting agreements and restrictions on transfer set forth therein cusip no k    d    page  of  pages   the agreement became effective upon the consummation of the may  offering on may   april  amendment warrants under the april  agreement in consideration of the agreements of pillar i and pillar ii under the agreement and the delivery of the waiver by pillar i and for no additional cash consideration the issuer agreed to issue to series d pillar warrants to purchase up to  shares of the issuers common stock these series d pillar warrants have an exercise price per share equal to  the pillar i warrants are exercisable immediately and will expire if not exercised on or prior to the fifth anniversary from the date of issuance the series d pillar warrants provide that after the second anniversary of the date of issuance the issuer may redeem the series d pillar warrants for  per share of common stock issuable on exercise of the series d pillar warrants following notice to the holder thereof if the closing price of the issuers common stock for  or more trading days in a period of  consecutive trading days is greater than or equal to  per share april  amendment agreement on april   pillar i pillar ii and besancon entered into an agreement with the issuer pursuant to which pillar i in its capacity as holder of  of the series d preferred stock irrevocably agreed to waive the right of the holders of the series d preferred stock under section  of the series d certificate of designations to receive in the event of a voluntary or involuntary liquidation dissolution or winding up of the issuer a liquidation an amount per share of series d preferred stock equal to the original issue price of such share of series d preferred stock plus any dividends accrued or declared but unpaid thereon to the extent such amount is greater than the amount that would have been payable with respect to such share had all shares of series d preferred stock been converted into shares of the issuers common stock immediately prior to such liquidation and that upon a liquidation the holders of the series d preferred stock will receive an amount per share of series d preferred stock equal to the amount that would be payable with respect to such share had all shares of series d preferred stock been converted into shares of the issuers common stock immediately prior to such liquidation in addition under the agreement pillar ii and besancon together the holders of  of the issuers series e preferred stock irrevocably agreed to waive the right of the holders of the series e preferred stock under section  of the series e certificate of designations to receive in the event of a liquidation an amount per share of series e preferred stock equal to the original issue price of such share of series e preferred stock plus any dividends accrued or declared but unpaid thereon to the extent such amount is greater than the amount that would have been payable with respect to such share had all shares of series e preferred stock been converted into shares of the issuers common stock immediately prior to such liquidation and that upon a liquidation the holders of the series e preferred stock will receive under section  of the series e certificate of designations an amount per share of series e preferred stock equal to the amount that would be payable with respect to such share had all shares of series e preferred stock been converted into shares of the issuers common stock immediately prior to such liquidation under the agreement the issuer agreed to seek approval from its stockholders at its  annual meeting of stockholders of amendments to the series d certificate of designations and series e certificate of designations to effect these changes to the liquidation provisions of the series d preferred stock and series e preferred stock and each of pillar i pillar ii and besancon agreed        to vote and to cause its affiliates to vote all shares of the issuers voting stock held by them or their affiliates and over which they have the power to vote in favor of such amendments and        not to and to cause their affiliates not to sell or transfer any shares of common stock series d preferred stock or series e preferred stock held by them to any person entity or group unless such proposed transferee agrees in a written instrument executed by such transferee the applicable entity and the issuer to take and hold such securities subject to among other things the agreement and to be bound by the terms of the agreement including the waiver of rights voting agreements and restrictions on transfer set forth therein the agreement became effective upon the consummation of the may  offering on may   april  amendment warrants in consideration of the agreements of pillar i pillar ii and besancon under the april  agreement and the delivery of the waivers by pillar i pillar ii and besancon and for no additional cash consideration the issuer agreed to issue to pillar i pillar ii and besancon warrants the pillarbesancon warrants and together with the series d pillar warrants the amendment warrants to purchase up to an aggregate of  shares of the issuers common stock with each of pillar i pillar ii and besancon receiving its pro rata portion thereof the pillarbesancon warrants have an exercise price per share equal to  cusip no k    d    page  of  pages   registration rights agreement in addition pillar i pillar ii and besancon entered into a registration rights agreement with the issuer pursuant to which the issuer agreed to file a registration statement with the securities and exchange commission regarding the resale of the shares of common stock issuable upon exercise of the amendment warrants the issuer will be subject to specified cash penalties if it fails to file and maintain an effective registration statement such penalties are limited to a cumulative maximum penalty equal to  of the aggregate exercise price of the amendment warrants then held by pillar i pillar ii and besancon which are not able to be sold pursuant to a registration statement the issuer will be required to use its reasonable best efforts to maintain the registration statements effectiveness until no shares of common stock issued or issuable upon exercise of the amendment warrants remain outstanding or issuable as applicable the foregoing descriptions of the amendment warrants the april  amendment agreement the april  amendment agreement and the registration rights agreement and of the terms the amended series d and series e preferred stock and amendment warrants  do not purport to be complete and are qualified in their entirety by the terms of each such document which are attached hereto as exhibit  exhibit  exhibit  exhibit  and exhibit  respectively and are incorporated herein by reference may  underwritten public offering on may   the issuer priced an underwritten public offering of its common stock and warrants to purchase common stock in that offering i pillar pharmaceuticals iii lp purchased  shares of common stock and warrants to purchase  shares of common stock from the underwriter for gross proceeds of  and ii besancon purchased  shares of common stock and warrants to purchase  shares of common stock from the underwriter for gross proceeds of  the public offering closed on may   september  underwritten public offering on september   the issuer priced an underwritten public offering of its common stock and warrants to purchase common stock in that offering i pillar pharmaceuticals iv lp purchased  shares of common stock from the underwriter for gross proceeds of  and ii besancon purchased  shares of common stock from the underwriter for gross proceeds of  the public offering closed on september   october  underwritten public offering on october   the issuer priced an underwritten public offering of its common stock in that offering i pillar pharmaceuticals v lp purchased  shares of common stock from the underwriter for gross proceeds of  and ii besancon purchased  shares of common stock from the underwriter for gross proceeds of  the public offering closed on october   additional disclosure the series d preferred stock series e preferred stock series d warrants series e warrants amendment warrants common stock and warrants to purchase common stock reported herein were acquired solely for investment purposes the reporting persons do not have any present plans or proposals that relate to or would result in any change in the business policies management structure or capitalization of the issuer the reporting persons will continue to evaluate the business and prospects of the issuer and its present and future interest in and intentions with respect to the issuer and in connection therewith expects from time to time to consult with management and other stockholders of the issuer the reporting persons reserve the right to formulate plans andor make proposals and take such actions with respect to their investment in the issuer including subject to applicable law i to hold its shares as a passive investor or as an active investor whether or not as a member of a group with other beneficial owners of shares or otherwise ii to acquire beneficial ownership of additional shares in the open market in privately negotiated transactions or otherwise iii to dispose of all or part of its holdings of the shares iv to take other actions which could involve one or more of the types of transactions or have one or more of the results described in item  of this amendment no  to schedule d or v to change its intention with respect to any or all of the matters referred to in this item  cusip no k    d    page  of  pages   other than as described above and as set forth in the series d transaction documents and the series e transaction documents and the related amendment agreements executed in connection with certain amendments to the series d and series e preferred stock the reporting persons do not have any plans or proposals which would result in any of the following a the acquisition by any person of additional securities of the issuer or the disposition of securities of the issuer b an extraordinary corporate transaction such as a merger reorganization or liquidation involving the issuer or any of its subsidiaries c a sale or transfer of a material amount of assets of the issuer or any of its subsidiaries d any change in the present board or management of the issuer including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board e any material change in the present capitalization or dividend policy of the issuer f any other material change in the issuers business or corporate structure g changes in the issuers charter bylaws or instruments corresponding thereto or other actions that may impede the acquisition of control of the issuer by any person h causing a class of securities of the issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association i a class of equity securities of the issuer becoming eligible for termination of registration pursuant to section g of the securities exchange act of  as amended or j any action similar to any of those enumerated above   item  interest in securities of the issuer a and b pillar directly holds i  shares of common stock and ii series d pillar warrants representing  shares of common stock pillar ii directly holds i  shares of common stock and ii series e pillar warrants representing  shares of common stock pillar iii directly holds  shares of common stock pillar iv directly holds  shares of common stock and pillar v directly holds  shares of common stock pillar gp as the general partner of pillar pillar ii pillar iii pillar iv and pillar v has investment discretion over the shares of pillar iii common stock series d pillar warrants series e pillar warrants pillar iii offering warrants and pillar iv and pillar v common stock directly held by pillar pillar ii pillar iii pillar iv and pillar v respectively pursuant to the advisory agreement pillar gp also has investment discretion over  shares of common stock series e pillar warrants representing  shares of common stock and warrants representing  shares of common stock that are held directly by besancon the besancon shares pursuant to rule d of the securities exchange act of  the exchange act the number of shares of common stock beneficially owned by the reporting persons and the applicable percentage represent prior to the application of the conversion cap and the voting cap a shares of common stock into which pillars shares of series d preferred stock are convertible assuming that only pillar converted its shares of series d preferred stock and that no other holder of series d preferred stock converted any shares of series d preferred stock b shares of common stock issued upon pillars exercise of its series d pillar warrants assuming that no other holder of series d pillar warrants exercisable for shares of common stock exercised any such series d pillar warrants c shares of common stock into which pillar iis shares of series e preferred stock are convertible assuming that only pillar ii converted its shares of series e preferred stock and that no other holder of series e preferred stock converted any shares of series e preferred stock d shares of common stock issued upon pillar iis exercise of its series e pillar warrants assuming that no other holder of series e pillar warrants exercisable for shares of common stock exercised any such series e pillar warrants e shares of common stock into which besancons shares of series e preferred stock are convertible assuming that only besancon converted its shares of series e preferred stock and that no other holder of series e preferred stock converted any shares of series e preferred stock f shares of common stock issued upon besancons exercise of its series e pillar warrants assuming that no other holder of series e pillar warrants exercisable for shares of common stock exercised any such series e pillar warrants g shares of common stock issued upon pillar iiis exercise of its pillar iii offering warrants assuming that no other holder of pillar iii offering warrants exercisable for shares of common stock exercised any such pillar iii offering warrants and h shares of common stock issued upon mr el zeins exercise of his vested options assuming that no other holder of options exercisable for shares of common stock exercises any such options as a result of the application of the conversion cap and the voting cap each of pillar pillar ii pillar iii pillar iv pillar v and pillar gp is reporting beneficial ownership  shares of common stock which represents  of the  shares of common stock outstanding as of the closing date pillar pillar ii pillar iii pillar iv pillar v and pillar gp expressly disclaim beneficial ownership of the shares of common stock held directly by mr el zein pillar pillar ii pillar iii pillar iv and pillar v expressly disclaim beneficial ownership of any of the besancon shares cusip no k    d    page  of  pages   mr el zein as director and controlling stockholder of pillar gp may be deemed to have sole power to direct the voting and disposition of the shares of common stock directly held by pillar pillar ii pillar iii pillar iv and pillar v and all shares that may be deemed to be beneficially owned by pillar gp which include the shares held directly by pillar pillar ii pillar iii pillar iv and pillar v and the besancon shares with respect to which pillar gp has investment discretion mr el zein also directly holds  shares of common stock and options to buy  shares of common stock which are exercisable within sixty days of the closing date as a result of the application of the conversion cap and the voting cap mr el zein is reporting beneficial ownership  shares of common stock which represents  of the  shares of common stock outstanding as of the closing date mr el zein expressly disclaims beneficial ownership of the shares of common stock held directly by pillar pillar ii pillar iii pillar iv and pillar v and indirectly by pillar gp including the besancon shares c except as described in this amendment no  to schedule d none of the reporting persons has effected any transaction in the securities of the issuer in the last  days d no persons other than the reporting persons and their investment clients have the right to participate in the receipt of dividends from or the proceeds from the sale of the shares of common stock covered hereby e not applicable   item  contracts arrangements understandings or relationships with respect to securities of the issuer the information set forth in item  hereof is hereby incorporated by reference into this item  except as referenced above or described in item  hereof there are no contracts arrangements understandings or relationships among the reporting persons or between such reporting persons and any other person with respect to any securities of the company cusip no k    d    page  of  pages   item  materials to be filed as exhibits exhibit     joint filing agreement as required by rule dk under the securities exchange act of  as amended exhibit     convertible preferred stock and warrant purchase agreement dated november   between the company and pillar incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     registration rights agreement between the company and pillar dated november   incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     certificate of designations preferences and rights of series d preferred stock of the company incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     form of warrant issued to purchaser pursuant to convertible preferred stock and warrant purchase agreement dated november   among the company and the pillar incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     convertible preferred stock and warrant purchase agreement dated november   between the company and pillar ii incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     registration rights agreement between the company and pillar ii dated november   incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     certificate of designations preferences and rights of series e preferred stock of the company incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     form of warrant issued to purchaser pursuant to convertible preferred stock and warrant purchase agreement dated november   among the company and the pillar incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     amendment no  to convertible preferred stock and warrant purchase agreement dated november   between the company and pillar incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     amendment no  to common stock purchase warrant dated november   between the company and pillar incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     form of warrant incorporated by reference to exhibit  to the issuers registration statement on form sa as filed with the securities and exchange commission on may   exhibit     form of prefunded warrant incorporated by reference to exhibit  to the issuers registration statement on form sa as filed with the securities and exchange commission on may   exhibit     agreement dated as of april   by and among the company pillar pharmaceuticals i lp and pillar pharmaceuticals ii lp incorporated by reference to exhibit  the issuers current report on form k as filed with the securities and exchange commission on april   exhibit     agreement dated april   by and among the company pillar pharmaceuticals i lp pillar pharmaceuticals ii lp and participations besancon incorporated by reference to exhibit  to the issuers registration statement on form sa as filed with the securities and exchange commission on may   cusip no k    d    page  of  pages   signature after reasonable inquiry and to the best of my knowledge and belief each of the undersigned hereby certifies that the information set forth in this statement is true complete and correct executed as a sealed instrument this th day of october    pillar pharmaceuticals i lp by pillar invest corporation its general partner by   s youssef el zein   name   youssef el zein   title   director pillar pharmaceuticals ii lp by pillar invest corporation its general partner by   s youssef el zein   name   youssef el zein   title   director   pillar pharmaceuticals iii lp by pillar invest corporation its general partner by   s youssef el zein   name   youssef el zein   title   director pillar pharmaceuticals iv lp by pillar invest corporation its general partner by   s youssef el zein name   youssef el zein title   director pillar pharmaceuticals v lp by pillar invest corporation its general partner by   s youssef el zein name   youssef el zein title   director pillar invest corporation by   s youssef el zein   name   youssef el zein   title   director s youssef el zein youssef el zein cusip no k    d    page  of  pages   exhibit index   exhibit     joint filing agreement as required by rule dk under the securities exchange act of  as amended exhibit     convertible preferred stock and warrant purchase agreement dated november   between the company and pillar incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     registration rights agreement between the company and pillar dated november   incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     certificate of designations preferences and rights of series d preferred stock of the company incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     form of warrant issued to purchaser pursuant to convertible preferred stock and warrant purchase agreement dated november   among the company and the pillar incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     convertible preferred stock and warrant purchase agreement dated november   between the company and pillar ii incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     registration rights agreement between the company and pillar ii dated november   incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     certificate of designations preferences and rights of series e preferred stock of the company incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     form of warrant issued to purchaser pursuant to convertible preferred stock and warrant purchase agreement dated november   among the company and the pillar incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     amendment no  to convertible preferred stock and warrant purchase agreement dated november   between the company and pillar incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     amendment no  to common stock purchase warrant dated november   between the company and pillar incorporated by reference to the issuers current report on form k as filed with the securities and exchange commission on november   exhibit     form of warrant incorporated by reference to exhibit  to the issuers registration statement on form sa as filed with the securities and exchange commission on may   exhibit     form of prefunded warrant incorporated by reference to exhibit  to the issuers registration statement on form sa as filed with the securities and exchange commission on may   exhibit     agreement dated as of april   by and among the company pillar pharmaceuticals i lp and pillar pharmaceuticals ii lp incorporated by reference to exhibit  the issuers current report on form k as filed with the securities and exchange commission on april   exhibit     agreement dated april   by and among the company pillar pharmaceuticals i lp pillar pharmaceuticals ii lp and participations besancon incorporated by reference to exhibit  to the issuers registration statement on form sa as filed with the securities and exchange commission on may   elevate your investments try it for free welcome to pillar pharma  your trusted canada contract manufacturing organization skip to main content your trusted  manufacturing partner  our vision to be the most competitive  valued solid dose  sterile ophthalmic contract manufacturing organization in canada competing in the global market home a foundation of excellence speed and flexibility set us apart and they depend on a foundation of quality service and reliability these are our  pillars if you require a rapid product launch or transfer or solutions to complex technical challenges you can depend on us to exceed your expectations at lightning speed this is pillar pharmas personal guarantee to you our five pillars idera pharmaceuticals inc idra pillar pharmaceuticals i lp maintains  stake in july edition of canna investorshub magazine now available support   newswire  home  log in boards stocks commodities forex cryptocurrency the lounge hot breakout boards ihub my stocks activity ticker buzz cloud most read most posted most followed members recent news active boards site stats new boards cannabis stocks tools data tools  charts trader alerts trades portfolio top lists price  news alerts commodities markets in d newswire more tools  newsletters my image gallery advanced search videos all news stock screener news filter live charts live news live desktop forex prices commodities etf center educational channel personal finance qa streamer level  follow feed home  boards  us listed  biotechs  idera pharmaceuticals inc idra pillar pharmaceuticals i lp maintains  stake in public reply  private reply  keep  last readpost new msgreplies   next   previous  next chmcnfunds   followed by  posts  boards moderated  alias born  idra current price volume bid ask days range idra detailed quote dmmmmyyyy statement of changes in beneficial ownership  edgar us regulatory    pm statement of changes in beneficial ownership  edgar us regulatory    am statement of changes in beneficial ownership  edgar us regulatory    pm idera announces fda orphan drug designation for imo for the treatment of melanoma globenewswire inc    pm statement of changes in beneficial ownership  edgar us regulatory    pm statement of changes in beneficial ownership  edgar us regulatory    pm statement of changes in beneficial ownership  edgar us regulatory    pm statement of changes in beneficial ownership  edgar us regulatory    pm statement of changes in beneficial ownership  edgar us regulatory    pm annual statement of changes in beneficial ownership  edgar us regulatory    pm current report filing k edgar us regulatory    pm amended statement of changes in beneficial ownership a edgar us regulatory    pm statement of changes in beneficial ownership  edgar us regulatory    pm idera to present at the jefferies  healthcare conference globenewswire inc    am current report filing k edgar us regulatory    am securities registration employee benefit plan s edgar us regulatory    pm quarterly report q edgar us regulatory    pm idera pharmaceuticals reports first quarter  financial results and provides corporate update globenewswire inc    pm statement of changes in beneficial ownership  edgar us regulatory    pm proxy statement definitive def a edgar us regulatory    pm statement of changes in beneficial ownership  edgar us regulatory    pm current report filing k edgar us regulatory    pm idera pharmaceuticals announces organizational update globenewswire inc    pm confidential treatment order ct order edgar us regulatory    am idera pharmaceuticals advances investigational treatment – intratumoral imo in combination with ipilimumab  for unmet globenewswire inc    am chmcnfunds   monday   am re none post  of   pillar pharmaceuticals i lp maintains  stake in idera pharmaceuticals inc idra october th    comments  filed under  by trevor kearing idera pharmaceuticals logopillar pharmaceuticals i lp revealed that they own  of idera pharmaceuticals inc nasdaqidra in a schedule da disclosure that was filed with the securities and exchange commission sec on monday october th the investor owns  shares of the stock worth about  the reporting parties listed on the disclosure included pillar pharmaceuticals i lp pillar pharmaceuticals ii lp pillar pharmaceuticals iii lp pillar pharmaceuticals iv lp pillar pharmaceuticals v lp pillar invest corporation and youssef el zein the filing is available through edgar at this link several other hedge funds and other institutional investors have also modified their holdings of the company jpmorgan chase  co raised its stake in shares of idera pharmaceuticals by  in the first quarter jpmorgan chase  co now owns  shares of the company’s stock worth  after buying an additional  shares during the period state street corp raised its position in shares of idera pharmaceuticals by  in the second quarter state street corp now owns  shares of the company’s stock worth  after buying an additional  shares during the period blackrock fund advisors raised its position in shares of idera pharmaceuticals by  in the second quarter blackrock fund advisors now owns  shares of the company’s stock worth  after buying an additional  shares during the period blackrock investment management llc raised its position in shares of idera pharmaceuticals by  in the second quarter blackrock investment management llc now owns  shares of the company’s stock worth  after buying an additional  shares during the period finally creative planning raised its position in shares of idera pharmaceuticals by  in the second quarter creative planning now owns  shares of the company’s stock worth  after buying an additional  shares during the period  of the stock is owned by institutional investors and hedge funds institutional ownership by quarter for idera pharmaceuticals nasdaqidra idera pharmaceuticals inc nasdaqidra opened at  on monday the firm’s market cap is  million the company’s  day moving average is  and its  day moving average is  idera pharmaceuticals inc has a month low of  and a month high of  idera pharmaceuticals nasdaqidra last released its earnings results on tuesday august nd the company reported  eps for the quarter hitting analysts’ consensus estimates of  idera pharmaceuticals had a negative net margin of  and a negative return on equity of  on average equities analysts anticipate that idera pharmaceuticals inc will post  earnings per share for the current year a number of equities analysts have weighed in on idra shares wedbush reiterated an “outperform” rating and issued a  price target on shares of idera pharmaceuticals in a report on tuesday august nd zacks investment research lowered shares of idera pharmaceuticals from a “buy” rating to a “hold” rating in a report on thursday august th finally sp equity research lifted their price target on shares of idera pharmaceuticals from  to  in a report on friday october th in other idera pharmaceuticals news director julian baker bought  shares of the company’s stock in a transaction that occurred on friday october th the shares were acquired at an average cost of  per share for a total transaction of  the purchase was disclosed in a legal filing with the sec which is available through this link  of the stock is currently owned by corporate insiders idera pharmaceuticals company profile idera pharmaceuticals inc is a clinicalstage biopharmaceutical company focused on the discovery development and commercialization of therapeutics for oncology and rare diseases the company utilizes two drug discovery technology platforms to design and develop drug candidates which include tolllike receptor tlr targeting technology and thirdgeneration antisense ga technology  httpwwwdailypoliticalcompillarpharmaceuticalsilpmaintainsstakeiniderapharmaceuticalsincidrahtml idra ihub newswire onci inks deal with major florida auto dealer law grouponci jul    am signal bay enters into definitive agreement to acquire viridis analytics ma llcsgby jul    am pura pps potential to reach  from current pura jul    am north road ventures advances to the detailed review stage in its acmpr applicationlib jul    am chron approved to officially uplist to the otcqb venture market immediately after going fullyreportingchro jul    pm start posting your companys news only  per official company press release public reply  private reply  keep  last readpost new msgreplies   next   previous  next follow board keyboard shortcuts report tos violation x current price change volume detailed quote  discussion board  to watchlist   investorshubcom inc about investor relations about us terms of service privacy policy advertise with us data accreditations disclaimer help faq handbook qa forum contact us tutorials educational educational channel stock market  educational videos investor help forum personal finance qa more corporate solutions ihub on facebook ihub on twitter ihub iphoneipad app ihub android app ihub blackberry app ihub newswire you are guest on web   pillar pharmaceuticals v lp  idera insider transactions  tipranks go prologin  sign up follow✓get real time transactionsinsider detailspillar pharmaceuticals v lpidera idradirector ten percent owner not rankedpillar pharmaceuticals v lps performancepillar pharmaceuticals v lp has not reported any informative transactions and therefore cannot be rankedhow are insiders ranked insider holdings  idera idramsee the top stocks by insiders  insider rolesidera idra director ten percent ownersee the top  corporate insiders  most profitable insider tradestock idera idratransaction type informative buydates oct    todaygain see the latest stocks traded by insiders  pillar pharmaceuticals v lps trading historybased on form  follow✓get real time transactionscompany nameinsider positionholding valuelast transactionlast transaction amountlast transaction dateidraideradirector ten percent ownerinformative buyundisclosedoct  pillar pharmaceuticals v lp has not reported any informative transactions for idra therefore performance cannot be measured track record datetransactionamountno of sharesprice per shareprofitform  oct   informative buy undisclosed   na see all insider trading from today you may also likemeet our smart portfolio see what top analysts say about your stocksget a breakdown of the different strategies based on detected insider trading activityfind the best performing analyst in each sector follow them so you never miss a recommendationrelated linkshow can i benefit from insider trading see the top  corporate insiders go to hot stocks by insiders find which stocks insiders traded today become a tipranks memberget the best investing tips  hacks straight to your emailfree membershipsubmitinsider trading daily newsletterprofessional daytrading strategy based on predictive insider transactionsannual return learn more powered by